ALT

Altimmune, Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website altimmune.com
Employees(FY) 52
ISIN US02155H2004

Performance

-8.78%

-12.02%

-4.73%

+1.9%

-10.68%

YTD

-31.78%

Profile

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Advanced Technical Analysis

Technical Analysis of ALT 2025-02-03

The stock indicators reflect a mixed sentiment, with a bearish Moving Average Score of 3 and a neutral Oscillators Score of 46, while the Technical Score of 7 indicates overall weakness. This combination suggests a cautious outlook, as the prevailing bearish signals may outweigh the neutral stance of the oscillators.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of ALT

Stock Rank

Recent News & Updates

2024-09-30 19:30
Altimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual Conference(Globenewswire)
2024-09-30 07:30
Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)(GlobeNewswire)
2024-09-29 19:30
Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)(Globenewswire)
2024-09-10 13:09
CORRECTION – Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes(GlobeNewswire)
2024-09-10 07:45
Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes(GlobeNewswire)
2024-09-10 01:09
CORRECTION Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes(Globenewswire)
2024-09-09 19:45
Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes(Globenewswire)
2024-09-03 07:30
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 60th Annual Meeting of the European Association for the Study of Diabetes(GlobeNewswire)
2024-09-02 19:30
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 60th Annual Meeting of the European Association for the Study of Diabetes(Globenewswire)
2024-08-10 09:03
Altimmune First Half 2024 Earnings: Revenues Beat Expectations, EPS Lags(Simply Wall St.)
2024-08-08 07:00
Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update(GlobeNewswire)
2024-08-07 19:00
Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update(Globenewswire)
2024-08-06 19:00
CytoSorbents to Report Second Quarter 2024 Operating and Financial Results(Yahoo Finance)
2024-08-01 08:47
With 56% ownership, Altimmune, Inc. (NASDAQ:ALT) boasts of strong institutional backing(Simply Wall St.)
2024-08-01 07:30
Altimmune to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024(GlobeNewswire)
2024-07-31 19:30
Altimmune to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024(Globenewswire)
2024-07-25 07:30
Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology(GlobeNewswire)
2024-07-24 19:30
Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology(Globenewswire)
2024-07-08 18:42
7 Bullish Stock Picks With the Potential to Turn $5K Into $50K(Investorplace)
2024-07-05 20:00
The 7 Best Under $10 Stocks to Buy in July 2024(Investorplace)
2024-07-02 07:30
Altimmune to Participate at Leerink Partners Therapeutics Forum(GlobeNewswire)
2024-07-01 19:30
Altimmune to Participate at Leerink Partners Therapeutics Forum(Globenewswire)
2024-06-27 22:09
The 3 Smartest Biotech Stocks to Buy With $5K Right Now(Investorplace)
2024-06-27 13:55
Altimmune, Inc. (ALT): Why Are Hedge Funds Shorting This Biopharmaceutical Stock?(Insidermonkey)
2024-06-26 11:08
What Is Short Selling In Stock Market? 15 Stocks Hedge Funds are Shorting(Insidermonkey)
2024-06-26 07:30
Altimmune Mourns Passing of Chief Financial Officer, Richard Eisenstadt(GlobeNewswire)
2024-06-25 19:30
Altimmune Mourns Passing of Chief Financial Officer, Richard Eisenstadt(Globenewswire)
2024-06-24 18:02
Crypto under pressure, Good Buy or Goodbye: Market Domination(Yahoo Finance Video)
2024-06-24 15:52
Altimmune reports positive results in weight-loss drug trial(Yahoo Finance Video)
2024-06-23 23:13
BITF Stock Alert: Riot Platforms Is Changing Its Approach to Take Over Bitfarms(Investorplace)

Page 2 of 8

previous next

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.